ORLANDO, Fla. — The inhaled insulin Afrezza combined with a long-acting basal analog offers a non-inferior insulin treatment option for people with type 1 diabetes, new phase 4 data suggest. Afrezza Inhalation Powder is a rapid-acting orally inhaled human insulin, approved by the US Food and Drug Administration in 2014 for treating adults with type …
